Pular para o conteúdo principal
Ranking Invest

EPRX - Eupraxia Pharmaceuticals Inc.

Segmento: HealthcareEupraxia Pharmaceuticals Inc., a clinical stage biotechnology company, engages in the discovery, development, and marketing of technologies in the biotechnology sector. The company's lead product candidates are EP-104IAR, which is in a Phase III clinical trial for the treatment of unmet medical needs and for pain relief for knee osteoarthritis; EP-104GI, which is in a Phase II clinical trial for the treatment of eosinophilic esophagitis; and EP-104, under preclinical studies for the treatment of other inflammatory joint conditions, benign structures of the esophagus, and epidural delivery. It also is involved in the development of product candidates for oncology. The company was formerly known as Plaza Capital Partners Inc. and changed its name to Eupraxia Pharmaceuticals Inc. in May 2012. Eupraxia Pharmaceuticals Inc. was incorporated in 2011 and is headquartered in Victoria, Canada.

Análise Ranking Invest

Valor de Mercado
$ 473.75 Mi
IVR
-0.12Índice proprietário de comparação relativa: -0,12.
IVR2
-0.18Leitura proprietária complementar: -18%.
MLL
-0.18Leitura proprietária complementar: -18%.
Último Balanço Atualizado: 1T2025

O Ranking Invest utiliza metodologia proprietária baseada em dados financeiros públicos; fórmulas e valores intermediários são confidenciais.

Dados da Empresa

Patrimônio Líquido

$ 30.17 Mi

Dívida Líquida

-$ 27.40 Mi

L4T

-$ 26.22 Mi

Indicadores Básicos

ROE

-86.90%

Índices de Previsibilidade

Receita Líquida

A0.00

Lucro

B0.19

Margem

A0.00

Índices de Tendência

Receita Líquida

D0.00

Lucro

F-5.60

Margem

D0.00

Índices de Endividamento

DIV/PAT

-0.91

DIV/L4T

1.04

Dívidas
Cotação
Gráfico Lucro/Receita Líquida X TrimestrePor padrão são exibidos os últimos 16 trimestres; quando houver mais trimestres disponíveis, use o botão junto à tabela de resultados para expandir o histórico.